B-cell receptor specific for HIV-1 Tat (BCR)

B-cell receptors (BCRs) specific for HIV-1 Tat epitopes are the primary immunological targets for vaccines designed to elicit a protective humoral response against the HIV-1 Trans-Activator of Transcription (Tat) protein. Tat is a critical regulatory protein secreted by HIV-infected cells that plays a vital role in viral gene expression, replication, and the induction of immune dysregulation. By specifically engaging BCRs that recognize conserved Tat epitopes, such as those in the N-terminal or cysteine-rich domains, therapeutic vaccines like vax-Tat aim to stimulate the expansion and differentiation of B cells into plasma cells that produce high-affinity anti-Tat antibodies. These antibodies neutralize extracellular Tat, preventing its uptake by non-infected cells and thereby mitigating its pro-apoptotic and immunosuppressive effects. This strategy is intended to complement antiretroviral therapy (ART) by reducing the viral reservoir and promoting immune restoration in HIV-infected individuals.

Other names

Tat-specific B-cell receptorAnti-Tat BCRB-cell receptor for HIV-1 Trans-Activator of TranscriptionHIV-1 Tat-specific B-cell receptor

Binding to and activation of specific B-cell receptors by Tat-derived immunogens to stimulate the expansion and differentiation of B cells into plasma cells that produce neutralizing anti-Tat antibodies.